Anide Johansen, PhD

The 5th Annual mRNA Therapeutics Summit brought together leaders from biotech, pharma, and academia to discuss the breakthroughs shaping RNA medicines and the bottlenecks that remain. Our recap highlights key takeaways, emerging opportunities, and the trends likely to define the next decade of RNA therapeutic development.

Micropeptides, proteins under 100 amino acids, are emerging regulators of cancer, metabolism, and neurodegeneration. Learn how ribosome profiling can reveal these hidden proteins, driving the discovery of new biomarkers and development of novel therapeutics.

RNA is unlocking the ability to develop life‑saving therapies at unprecedented speed. The recent success with baby KJ demonstrates how RNA medicine can move a personalized treatment from diagnosis to clinic in less than a year.

Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE™ portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design.